Drug-target residence time and its implications for lead optimization
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromolecules by low-molecular-mass drugs. The binding of drugs to their macromolecular targets is therefore seen as paramount for pharmacological activity. In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC(50) or K(d). This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex. We describe the potential advantages of long residence time in terms of duration of pharmacological effect and target selectivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The translation between slow inhibitor binding kinetics and sustained pharmacodynamic modulation has been studied for a numberoftarget classes (58).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [58]
In the citing paper
“Furthermore, the targets of infectious diseases usually have high replication rates, while covalent inhibitors tend to have long residence times making them less effective in this area [128].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [128]
In the citing paper
“Furthermore, longer residence times of drugs with their targets, as a result of slower off-rates, is a useful mechanism to extend in-vivo efficacy (59–61).”
From A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit (2026) · cites this paper as [59]
Citations
Cites
Catalysis in chemistry and enzymology
Jencks, W. P. (1969) · Medical Entomology and Zoology · Cited by 3,217
Structure and Mechanism in Protein Science
Fersht, A. (1998) · Cited by 1,882
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Self-citationLiang, J., Woodward, C., & Edelsbrunner, H. (1998) · Protein Science · doi:10.1002/pro.5560070905 · Cited by 1,057
Enzymes: a practical introduction to structure, mechanism, and data analysis
(2001) · Choice Reviews Online · doi:10.5860/choice.38-3881 · Cited by 1,056
Optical biosensors in drug discovery
Cooper, M. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd838 · Cited by 1,015
Oppenheimer, N. J., & James, T. L. (1989) · Academic Press eBooks · Cited by 820
Rusnak, D. W., Lackey, K. E., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Murray, D. M., Knight, W. B., Mullin, R. J., et al. (2001) · PubMed · Cited by 728
Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis
Copeland, R. A. (2000) · Wiley eBooks · doi:10.1002/0471220639 · Cited by 726
Self-citation
Cited by
Items 301–400 of 1,003
Chang, A. T., Schiebel, J., Yu, W., Bommineni, G. R., Pan, P., Baxter, M. V., Khanna, A., Sotriffer, C., Kisker, C., & Tonge, P. J. (2013) · Biochemistry · doi:10.1021/bi400413c · Cited by 63
Long Residence Time Inhibition of EZH2 in Activated Polycomb Repressive Complex 2
Aller, G. S. V., Pappalardi, M. B., Ott, H. M., Diaz, E., Brandt, M. A., Schwartz, B., Miller, W. H., Dhanak, D., McCabe, M. T., Verma, S. K., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb4008748 · Cited by 62
Wang, A., Dorso, C. R., Kopcho, L. M., Locke, G. A., Langish, R. A., Harstad, E. B., Shipkova, P. A., Marcinkeviciene, J. A., Hamann, L. G., & Kirby, M. (2012) · BMC Pharmacology · doi:10.1186/1471-2210-12-2 · Cited by 59
Resistance to HIV integrase inhibitors
Mésplède, T., Quashie, P. K., & Wainberg, M. A. (2012) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328356db89 · Cited by 63
Escape of a Small Molecule from Inside T4 Lysozyme by Multiple Pathways
Nunes‐Alves, A., Zuckerman, D. M., & Arantes, G. M. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.01.014 · Cited by 60
Schuetz, D. A., Richter, L., Amaral, M., Grandits, M., Grädler, U., Müsil, D., Buchstaller, H., Eggenweiler, H., Frech, M., & Ecker, G. F. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00080 · Cited by 60
Ensemble-Based Steered Molecular Dynamics Predicts Relative Residence Time of A2A Receptor Binders
Potterton, A., Husseini, F. S., Southey, M. W. Y., Bodkin, M. J., Heifetz, A., Coveney, P. V., & Townsend‐Nicholson, A. (2019) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.8b01270 · Cited by 62
Pharmacokinetic–pharmacodynamic models that incorporate drug–target binding kinetics
Daryaee, F., & Tonge, P. J. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.03.008 · Cited by 64
Drug Design in the Exascale Era: A Perspective from Massively Parallel QM/MM Simulations
Raghavan, B., Paulikat, M., Ahmad, K., Callea, L., Rizzi, A., Ippoliti, E., Mandelli, D., Bonati, L., Vivo, M. D., & Carloni, P. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00557 · Cited by 63
Lin, Y., Greenwood, A., Nicholson, L. K., Sharma, Y., McDonough, S. P., & Chang, Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.031369 · Cited by 60
Guan, Y., Shan, X., Zhang, F., Wang, S., Chen, H., & Tao, N. J. (2015) · Science Advances · doi:10.1126/sciadv.1500633 · Cited by 59
Nanomolar E-Selectin Antagonists with Prolonged Half-Lives by a Fragment-Based Approach
Egger, J., Weckerle, C., Cutting, B., Schwardt, O., Rabbani, S., Lemme, K., & Ernst, B. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4029582 · Cited by 59
Tang, Z., & Chang, C. A. (2017) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.7b00899 · Cited by 59
Surface Plasmon Resonance Biosensors: A Review of Molecular Imaging with High Spatial Resolution
Xu, J., Zhang, P., & Chen, Y. (2024) · Biosensors · doi:10.3390/bios14020084 · Cited by 56
Ramsey, S. J., Attkins, N., Fish, R. L., & van der Graaf, P. H. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01390.x · Cited by 56
Björkelund, H., Gedda, L., & Andersson, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016536 · Cited by 56
Louvel, J., Guo, D. M., Agliardi, M., Mocking, T. A. M., Kars, R., Pham, T. P., Xia, L., de Vries, H., Brussee, J., Heitman, L. H., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401643m · Cited by 58
Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor
Tomassi, S., Lategahn, J., Engel, J., Keul, M., Tumbrink, H. L., Ketzer, J., Mühlenberg, T., Baumann, M., Schultz‐Fademrecht, C., Bauer, S., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01626 · Cited by 58
Molecular properties affecting fast dissociation from the D2 receptor
Tresadern, G., Bartolomé, J. M., Macdonald, G. J., & Langlois, X. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.02.033 · Cited by 57
Anderson, K., Lai, Z., McDonald, O. B., Stuart, J. D., Nartey, E. N., Hardwicke, M. A., Newlander, K. A., Dhanak, D., Adams, J. L., Patrick, D. R., et al. (2009) · Biochemical Journal · doi:10.1042/bj20090121 · Cited by 55
Self-citationSimard, J. R., Getlik, M., Grütter, C., Schneider, R., Wulfert, S., & Rauh, D. (2010) · Journal of the American Chemical Society · doi:10.1021/ja908083e · Cited by 60
Miller, D. C., Lunn, G., Jones, P., Sabnis, Y. A., Davies, N. L., & Driscoll, P. C. (2012) · MedChemComm · doi:10.1039/c2md00270a · Cited by 55
Sun, H., Li, Y., Shen, M., Li, D., Kang, Y., & Hou, T. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00075 · Cited by 56
Zheng, M., Zhao, J., Cui, C., Fu, Z., Li, X., Liu, X., Ding, X., Tan, X., Li, F., Luo, X., et al. (2018) · Medicinal Research Reviews · doi:10.1002/med.21483 · Cited by 59
Li, L., Su, M., Lu, W., Song, H., Liu, J., Wen, X., Suo, Y., Qi, J., Luo, X., Zhou, Y., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00127 · Cited by 54
Geometric Deep Learning for Structure-Based Ligand Design
Powers, A. S., Yu, H. H., Suriana, P., Koodli, R. V., Lu, T., Paggi, J. M., & Dror, R. O. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00572 · Cited by 66
Prediction of Drug–Target Binding Kinetics by Comparative Binding Energy Analysis
Ganotra, G. K., & Wade, R. C. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00397 · Cited by 54
Ranking Reversible Covalent Drugs: From Free Energy Perturbation to Fragment Docking
Zhang, H., Jiang, W., Chatterjee, P., & Luo, Y. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00959 · Cited by 57
Kokh, D. B., Kaufmann, T., Kister, B., & Wade, R. C. (2019) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00036 · Cited by 54
Ribeiro, J. M. L., Provasi, D., & Filizola, M. (2020) · The Journal of Chemical Physics · doi:10.1063/5.0019100 · Cited by 54
Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology
LoRusso, P. M., & Eder, J. P. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.7.1013 · Cited by 56
Structure-based discovery of cyclin-dependent protein kinase inhibitors
Martin, M. P., Endicott, J., & Noble, M. E. M. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170040 · Cited by 56
Structure, Thermodynamics, and Kinetics of Plinabulin Binding to Two Tubulin Isotypes
Sala, G. L., Olieric, N., Sharma, A., Viti, F., Balaguer, F. D. A., Huang, L., Tonra, J. R., Lloyd, G. K., Decherchi, S., Díaz, J. F., et al. (2019) · Chem · doi:10.1016/j.chempr.2019.08.022 · Cited by 55
Wolf, S., Amaral, M., Lowinski, M., Vallée, F., Müsil, D., Güldenhaupt, J., Dreyer, M. K., Bomke, J., Frech, M., Schlitter, J., et al. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00592 · Cited by 60
Oguro, Y., Cary, D. R., Miyamoto, N., Tawada, M., Iwata, H., Miki, H., Hori, A., & Imamura, S. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.04.042 · Cited by 53
A guide to enzyme kinetics in early drug discovery
Srinivasan, B. (2022) · FEBS Journal · doi:10.1111/febs.16404 · Cited by 55
Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases
Talekar, M., Tran, T.-H., & Amiji, M. M. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9772-2 · Cited by 56
Brandt, T., Holzmann, N., Muley, L., Khayat, M. T. A., Gerlach, C., Baum, B., Heine, A., Hangauer, D. G., & Klebe, G. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.11.038 · Cited by 52
Wang, W., Yin, L., Gonzalez-Malerva, L. G., Wang, S., Yu, X., Eaton, S., Zhang, S., Chen, H., LaBaer, J., & Tao, N. J. (2014) · Scientific Reports · doi:10.1038/srep06609 · Cited by 54
Sarott, R. C., Westphal, M. V., Pfaff, P., Korn, C., Sykes, D. A., Gazzi, T., Brennecke, B., Atz, K., Weise, M., Mostinski, Y., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c05587 · Cited by 53
Perspectives on High-Throughput Ligand/Protein Docking With Martini MD Simulations
Souza, P. C. T., Limongelli, V., Wu, S., Marrink, S. J., & Monticelli, L. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.657222 · Cited by 47
Solowiej, J. E., Bergqvist, S., McTigue, M. A., Marrone, T. J., Quenzer, T. L., Cobbs, M., Ryan, K., Kania, R. S., Diehl, W. C., & Murray, B. W. (2009) · Biochemistry · doi:10.1021/bi900522y · Cited by 52
Neumann, L., von König, K., & Ullmann, D. (2011) · Methods in Enzymology · doi:10.1016/b978-0-12-381274-2.00012-1 · Cited by 51
Binding Kinetics of ZM241385 Derivatives at the Human Adenosine A2A Receptor
Guo, D. M., Xia, L., van Veldhoven, J. P. D., Hazeu, M., Mocking, T. A. M., Brussee, J., IJzerman, A. P., & Heitman, L. H. (2014) · ChemMedChem · doi:10.1002/cmdc.201300474 · Cited by 51
Schiebel, J., Kapilashrami, K., Fekete, Á., Bommineni, G. R., Schaefer, C. M., Mueller, M. J., Tonge, P. J., & Kisker, C. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.511436 · Cited by 51
Miyahisa, I., Sameshima, T., & Hixon, M. S. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201505800 · Cited by 49
Fragment‐Based De Novo Design Reveals a Small‐Molecule Inhibitor of Helicobacter Pylori HtrA
Perna, A. M., Rodrigues, T., Schmidt, T. P., Böhm, M., Stutz, K., Reker, D., Pfeiffer, B., Altmann, K., Backert, S., Weßler, S., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201504035 · Cited by 51
Binding Kinetics in Drug Discovery
Ferruz, N., & Fabritiis, G. D. (2016) · Molecular Informatics · doi:10.1002/minf.201501018 · Cited by 55
Bouzo-Lorenzo, M., Stoddart, L. A., Xia, L., IJzerman, A. P., Heitman, L. H., Briddon, S. J., & Hill, S. J. (2019) · Purinergic Signalling · doi:10.1007/s11302-019-09650-9 · Cited by 57
Basu, D., Richters, A., & Rauh, D. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.04.038 · Cited by 50
Discovery of TAK-960: An orally available small molecule inhibitor of polo-like kinase 1 (PLK1)
Nie, Z., Feher, V. A., Natala, S. R., McBride, C. M., Kiryanov, A. A., Jones, B., Lam, B., Liu, Y., Kaldor, S. W., Stafford, J. A., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.02.083 · Cited by 50
Mechanism of Action Assays for Enzymes
Strelow, J. M., Dewé, W., Iversen, P. W., Brooks, H. B., Radding, J. A., McGee, J. E., & Weidner, J. R. (2012) · Cited by 50
Conformation-Specific Effects of Raf Kinase Inhibitors: Miniperspective
Wang, X., & Kim, J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300613w · Cited by 48
Ligand Release Pathways Obtained with WExplore: Residence Times and Mechanisms
Dickson, A., & Lotz, S. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b04012 · Cited by 50
Davis, T. M. E. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12295 · Cited by 50
Zervosen, A., Herman, R., Kerff, F., Herman, A., Bouillez, A., Prati, F., Pratt, R. F., Frère, J., Joris, B., Luxen, A., et al. (2011) · Journal of the American Chemical Society · doi:10.1021/ja200696y · Cited by 49
Willemsen‐Seegers, N., Uitdehaag, J. C. M., Prinsen, M. B. W., de Vetter, J. R. F., de Man, J., Sawa, M., Kawase, Y., Buijsman, R. C., & Zaman, G. J. R. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.12.019 · Cited by 51
Fabini, E., & Danielson, U. H. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.03.054 · Cited by 49
Fischer, M. M., Leech, A., & Hubbard, R. E. (2011) · Analytical Chemistry · doi:10.1021/ac103168q · Cited by 49
Quantifying Biological Activity in Chemical Terms: A Pharmacology Primer To Describe Drug Effect
Kenakin, T. (2009) · ACS Chemical Biology · doi:10.1021/cb800299s · Cited by 49
Devogelaere, B., Berke, J. M., Vijgen, L., Dehertogh, P., Fransen, E., Cleiren, E., van der Helm, L., Nyanguile, O., Tahri, A., Amssoms, K., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00245-12 · Cited by 48
Jagger, B. R., Ojha, A. A., & Amaro, R. E. (2020) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.0c00495 · Cited by 52
Shapiro, G. I., McCallum, S. W., Adams, L. M., Sherman, L. J., Weller, S., Swann, S., Keer, H. N., Miles, D., Müller, T. R., & LoRusso, P. M. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9881-z · Cited by 48
Fieulaine, S., Boularot, A., Artaud, I., Desmadril, M., Dardel, F., Meinnel, T., & Giglione, C. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001066 · Cited by 51
Analgesic Effect of Highly Reversible ω-Conotoxin FVIA on N Type Ca 2+ Channels
Lee, S., Kim, Y., Back, S. K., Choi, H.-W., Lee, J. Y., Jung, H. H., Ryu, J. H., Suh, H., Na, H. S., Kim, H. J., et al. (2010) · Molecular Pain · doi:10.1186/1744-8069-6-97 · Cited by 48
Drug-target interaction/affinity prediction: Deep learning models and advances review
Vefghi, A., Rahmati, Z., & Akbari, M. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110438 · Cited by 58
Meur, A. M., Ghisdal, P., Mullier, B., Ron, P. D., Downey, P. M., Perren, C. V. D., Declercq, V., Cornelis, S., Famelart, M., van Asperen, J., et al. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12343 · Cited by 53
Is there a link between selectivity and binding thermodynamics profiles?
Tarcsay, Á., & Keserű, G. M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.014 · Cited by 50
Oligonucleotide-mediated tRNA sequestration enables one-pot sense codon reassignment in vitro
Cui, Z., Wu, Y., Mureev, S., & Alexandrov, K. A. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky365 · Cited by 48
Dynamics of human protein kinase Aurora A linked to drug selectivity
Pitsawong, W., Buosi, V., Otten, R., Agafonov, R. V., Zorba, A., Kern, N., Kutter, S., Kern, G., Pádua, R. A., Meniche, X., et al. (2018) · eLife · doi:10.7554/elife.36656 · Cited by 44
Current Strategies and Applications for Precision Drug Design
Wang, C., Xu, P., Zhang, L., Huang, J. L., Zhu, K., & Luo, C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00787 · Cited by 49
Quantitative, Real-Time Measurements of Intracellular Target Engagement Using Energy Transfer
Robers, M. B., Vasta, J. D., Corona, C. R., Ohana, R. F., Hurst, R., Jhala, M. A., Comess, K. M., & Wood, K. V. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8891-4_3 · Cited by 47
Shekhar, M., Smith, Z., Seeliger, M. A., & Tiwary, P. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202200983 · Cited by 53
Protein-Induced Long Lifetime Luminescence of Nonmetal Probes
Enkvist, E., Vaasa, A., Kasari, M., Kriisa, M., Ivan, T., Ligi, K., Raidaru, G., & Uri, A. (2011) · ACS Chemical Biology · doi:10.1021/cb200120v · Cited by 47
On-rate based optimization of structure–kinetic relationship – surfing the kinetic map
Schoop, A., & Dey, F. (2015) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2015.08.003 · Cited by 46
Vauquelin, G. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1067196 · Cited by 49
Biophysical Methods in Drug Discovery from Small Molecule to Pharmaceutical
Holdgate, G. A., Geschwindner, S., Breeze, A. L., Davies, G. M., Colclough, N., Temesi, D. G., & Ward, L. T. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-398-5_12 · Cited by 54
Flood, D. G., Marek, G. J., & Williams, M. J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.01.021 · Cited by 49
Jung, S., Fuchs, N. S., Johé, P., Wagner, A., Diehl, E., Yuliani, T., Zimmer, C., Barthels, F., Zimmermann, R. A., Klein, P., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01002 · Cited by 46
Decisive role of water and protein dynamics in residence time of p38α MAP kinase inhibitors
Pantsar, T., Kaiser, P. D., Kudolo, M., Förster, M., Rothbauer, U., & Laufer, S. (2022) · Nature Communications · doi:10.1038/s41467-022-28164-4 · Cited by 48
How hydrophobic drying forces impact the kinetics of molecular recognition
Mondal, J., Morrone, J. A., & Berne, B. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312529110 · Cited by 47
Kolář, M. H., Hostaš, J., & Hobza, P. (2015) · Physical Chemistry Chemical Physics · doi:10.1039/c5cp90146d · Cited by 47
Reversible Covalent Inhibition─Desired Covalent Adduct Formation by Mass Action
Patel, D., Huma, Z. E., & Duncan, D. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.3c00805 · Cited by 50
Slow Onset Inhibition of Bacterial β-Ketoacyl-acyl Carrier Protein Synthases by Thiolactomycin
Machutta, C. A., Bommineni, G. R., Luckner, S. R., Kapilashrami, K., Ruzsicska, B. P., Simmerling, C. L., Kisker, C., & Tonge, P. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.077909 · Cited by 45
CNS Anticancer Drug Discovery and Development Conference White Paper
Levin, V. A., Tonge, P. J., Gallo, J. M., Birtwistle, M. R., Dar, A. C., Iavarone, A., Paddison, P. J., Heffron, T. P., Elmquist, W. F., Lachowicz, J. E., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov169 · Cited by 47
Sahner, J. H., Brengel, C., Storz, M. P., Groh, M., Plaza, A., Müller, R., & Hartmann, R. W. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401102e · Cited by 45
Investigating Drug–Target Residence Time in Kinases through Enhanced Sampling Simulations
Gobbo, D., Piretti, V., Martino, R. M. C. D., Tripathi, S. K., Giabbai, B., Storici, P., Demitri, N., Girotto, S., Decherchi, S., & Cavalli, A. (2019) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.9b00104 · Cited by 48
Defining the Role of Pharmacology in the Emerging World of Translational Research
Enna, S. J., & Williams, M. J. (2009) · Advances in pharmacology · doi:10.1016/s1054-3589(08)57001-3 · Cited by 49
Prosser, G. A., & de Carvalho, L. P. S. (2013) · Biochemistry · doi:10.1021/bi400839f · Cited by 44
Lin, Y., Greenwood, A., Yan, W., Nicholson, L. K., Sharma, Y., McDonough, S. P., & Chang, Y. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.08.089 · Cited by 47
Storz, M. P., Allegretta, G., Kirsch, B., Empting, M., & Hartmann, R. W. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob00707g · Cited by 44
Wang, J., Guo, Z., Fu, Y., Wu, Z., Huang, C., Zheng, C., Shar, P. A., Wang, Z., Xiao, W., & Wang, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw018 · Cited by 49
Kinetics of Ligand–Protein Dissociation from All-Atom Simulations: Are We There Yet?
Ribeiro, J. M. L., Tsai, S.-T., Pramanik, D., Wang, Y., & Tiwary, P. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00977 · Cited by 47
Recent development of leucyl-tRNA synthetase inhibitors as antimicrobial agents
Zhang, P., & Ma, S. (2019) · MedChemComm · doi:10.1039/c9md00139e · Cited by 44
Grobben, Y., Uitdehaag, J. C. M., Willemsen‐Seegers, N., Tabak, W. W. A., de Man, J., Buijsman, R. C., & Zaman, G. J. R. (2019) · Journal of Structural Biology X · doi:10.1016/j.yjsbx.2019.100014 · Cited by 55
Iannelli, G., Milite, C., Marechal, N., Cura, V., Bonnefond, L., Troffer-Charlier, N., Feoli, A., Rescigno, D., Wang, Y., Cipriano, A., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00252 · Cited by 44
Kawakita, Y., Banno, H., Ohashi, T., Tamura, T., Yusa, T., Nakayama, A., Miki, H., Iwata, H., Kamiguchi, H., Tanaka, T., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300185p · Cited by 48
Niu, Y., Li, S., Pan, D., Liu, H., & Yao, X. (2016) · Physical Chemistry Chemical Physics · doi:10.1039/c5cp06257h · Cited by 44
An updated patent review of anticancer Hsp90 inhibitors (2013-present)
Li, L., Chen, N., You, Q., & Xu, X. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1829595 · Cited by 44
SEEKR2: Versatile Multiscale Milestoning Utilizing the OpenMM Molecular Dynamics Engine
Votapka, L. W., Stokely, A. M., Ojha, A. A., & Amaro, R. E. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00501 · Cited by 50
Metadata
- Authors
- Copeland, R. A., Pompliano, D. L., & Meek, T. D.
- Affiliations
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Copeland, Robert A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-08-04
- Volume
- 5
- Issue
- 9
- Pages
- 730-739
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2016408686
- Semantic Scholar
- 362824beb2008831aa65b4eb774e5c8703ff9c71
- Cited by
- 1,464
- References
- 46
- Citations by year
- 2026: 83 · 2025: 64 · 2024: 78 · 2023: 79 · 2022: 81 · 2021: 76 · 2020: 83 · 2019: 88 · 2018: 102 · 2017: 104 · 2016: 96 · 2015: 120 · 2014: 74 · 2013: 88 · 2012: 65
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Interaction Studies and Fluorescence Analysis
- Keywords
- drug-target residence time, lead optimization, drug selectivity, drug-target binding, binding affinity
- MeSH terms
- Binding, Competitive, Pharmaceutical Preparations, Humans, Kinetics, Ligands, Technology, Pharmaceutical, Drug Design, Drug Delivery Systems, Macromolecular Substances
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.